Abstract
Summary During the Third International Symposium, a leading panel of experts in the field discussed the current most prominent problems in the treatment of Hodgkin's disease to give recommendations for future clinical trials. Within the workshop on clinical trials the following issues were addressed: 1. Which diagnostic procedures are state of the art and to what extent are they able to contribute to a so-called response- adapted treatment (RAT)? 2. What is the optimal dose and volume of radiotherapy in different stages? 3. What is the value of chemotherapy in early stages and is it restricted to a certain subgroup? 3. Have we achieved as much as we can in intermediate stages in terms of response with now focusing future efforts on reducing toxicity and improving quality of live? 5. Is high-dose chemotherapy (HDCT) the answer to the challenge of improving treatment results in advanced stages? 6. What is the optimal schedule and dose of HDCT and consecutive autologous bone marrow transplantation (ABMT)?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
